Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

RABEPRAZOLE SODIUM

All products: general benefit

Other products in the same Health Canada class (A02BC) — coverage varies; not interchangeable

  • Pantoprazole (Tecta): general benefit
  • Lansoprazole (Prevacid): limited Use 293, 295, 297, 401, 402
  • Omeprazole (Losec DR Tab): limited Use 293, 297, 401, 402, Not a benefit
  • Pantoprazole (Pantoloc): limited Use 293, 295, 297, 401, 402, Not a benefit
  • Dexlansoprazole (Dexilant): not a benefit
  • Esomeprazole (Nexium DR Tab): not a benefit

7 more in the class list below

Pariet · DIN 02243796 · 10mg · tablet

General benefitMarketed · checked 2026-09-19
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Pariet · DIN 02243796 Manufacturer: Janssen Inc.; listing date 2002-07-29 Health Canada: Marketed since 2002-04-02 · brand PARIET, ENTERIC-COATED TABLET 10MG · ATC A02BC04 RABEPRAZOLE · form Tablet (enteric-coated) · route Oral · ingredients RABEPRAZOLE SODIUM 10 MG · company Janssen inc · schedule Prescription
Check this DIN again · Health Canada product record

Ministry pays: $0.0669 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=67734 · Verify on the e-Formulary ↗ (DIN 02243796)

Source record
DIN 02243796: Pariet Raw flags: chronicUseMed=Y, sec3=Y Item: 564000098; group id 696; item number 1719; lccId None; manufacturer id JAN Source form: Tab; strength: 10mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $1.6598; ministry $0.0669 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02243796 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=67734
Interchangeable products
Apo-Rabeprazole · DIN 02345579 · $0.0669 Jamp Rabeprazole · DIN 02415283 · $0.0669 Rabeprazole · DIN 02385449 · $0.0669 Rabeprazole EC · DIN 02356511 · $0.0669 Ran-Rabeprazole · DIN 02298074 · $0.0669 Sandoz Rabeprazole · DIN 02314177 · $0.0669 Teva-Rabeprazole EC · DIN 02296632 · $0.0669
Shortage status: not checked (no credentials)
Other drugs in the same formulary class (56:40 Miscellaneous G.I. Drugs) and how they are covered

Matched class: 56:40 Miscellaneous G.I. Drugs

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: BUDESONIDE, MESALAZINE, NIZATIDINE, OLSALAZINE SODIUM, PANTOPRAZOLE MAGNESIUM, SUCRALFATE Some products covered without a code (check the product listing): 5-AMINOSALICYLIC ACID, CIMETIDINE, DOMPERIDONE MALEATE, FAMOTIDINE, LACTULOSE, METOCLOPRAMIDE HCL, MISOPROSTOL, RANITIDINE HCL 56:40 Miscellaneous G.I. Drugs

PANTOPRAZOLE MAGNESIUM

· 6 products · General benefit · strengths: 40mg · Ent Coated Tab

LANSOPRAZOLE

· 16 products · Limited Use, codes 293, 295, 297, 401, 402 · strengths: 15mg, 30mg · DR Cap

OMEPRAZOLE

· 19 products · Off-Formulary Interchangeable, not an ODB benefit (4), Listed, not a benefit (2), Limited Use, codes 293, 297, 401, 402 (13) · strengths: 10mg, 20mg · DR Cap

PANTOPRAZOLE SODIUM

· 30 products · Off-Formulary Interchangeable, not an ODB benefit (10), Limited Use, codes 293, 295, 297, 401, 402 (20) · strengths: 20mg, 40mg · Ent Tab

DEXLANSOPRAZOLE

· 6 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 30mg, 60mg · DR Cap

ESOMEPRAZOLE

· 22 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 40mg, 20mg · DR Tab

CIMETIDINE

· 10 products · General benefit (5), Listed, not a benefit (5) · strengths: 200mg, 300mg, 400mg, 600mg, 800mg · Tab

FAMOTIDINE

· 16 products · Listed, not a benefit (2), General benefit (14) · strengths: 20mg, 40mg · Tab

MISOPROSTOL

· 4 products · Listed, not a benefit (2), General benefit (2) · strengths: 100mcg, 200mcg · Tab

NIZATIDINE

· 2 products · General benefit · strengths: 150mg, 300mg · Cap

RANITIDINE HCL

· 23 products · Listed, not a benefit (3), General benefit (20) · strengths: 15mg/mL, 150mg, 300mg · Oral Sol, Tab

SUCRALFATE

· 4 products · General benefit · strengths: 1g/5mL, 1g · Oral Susp, Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 56:40 and 10 more
Full class listing Related classes: 56:04 Antacids and Adsorbents, 56:08 Antidiarrhea Agents, 56:12 Cathartics, 56:16 Digestants, 56:22 Antiemetics and Antinauseants Same formulary class, not same indication: class membership alone does not establish equivalent uses.
Other drugs whose Health Canada label lists a similar indication: conditions where a reduction of gastric acid secretion is required
From Health Canada product monographs; label wording only, not a treatment recommendation. Matching is lexical and uses one held product label per generic; formulations and qualifying criteria may differ. Covered without a code on the Ontario formulary: PANTOPRAZOLE MAGNESIUM PANTOPRAZOLE MAGNESIUM · General benefit INDICATIONS TECTA® (pantoprazole magnesium) is indicated for the treatment of conditions where a reduction of gastric acid secretion is required, such as the following: • Duodenal ulcer • Gastric ulcer • Reflux esophagitis • Symptomatic gastro-esophageal reflux disease (such as, acid regurgitation and heartburn) • Helicobacter pylori (H. pylori) associated duodenal ulcer Pantoprazole, in combination with clarithromycin and either amoxicillin or metronidazole, is indicated for the treatment of patients with an active duodenal ulcer who are H. pylori positive (see 4 DOSAGE AND ADMINISTRATION and 14 CLINICAL TRIALS). PM: https://pdf.hres.ca/dpd_pm/00070181.PDF; date MAR 30, 2023; DIN 02267233; fetched 2026-09-10 Product monograph Coverage source: ON formulary extract 2026-08-26
What the Health Canada label says it is for
1 INDICATIONS PARIET ® (rabeprazole sodium) is indicated for treatment of conditions where a reduction of gastric acid secretion is required, such as:  Symptomatic relief and healing of erosive or ulcerative gastroesophageal reflux disease (GERD).  Long-term maintenance of healing of erosive or ulcerative gastroesophageal reflux disease (GERD).  Treatment of symptoms (i.e., heartburn and regurgitation) in symptomatic gastroesophageal reflux disease (GERD), also called non-erosive reflux disease (NERD).  Symptomatic relief and healing of duodenal ulcers.  Symptomatic relief and healing of gastric ulcers.  Long-term treatment of pathological hypersecretory conditions, including Zollinger - Ellison syndrome.  Eradication of Helicobacter pylori (H. pylori) associated with duodenal ulcer disease (active or history within the past 5 years). Rabeprazole, in combination with appropriate antibacterial therapeutic regimens such as amoxicillin and clarithromycin, is indicated for the treatment of patients with duodenal ulcer disease associated with H. pylori infection. Eradication of H. py… https://pdf.hres.ca/dpd_pm/00066947.PDF PM date: May 7, 2001 Source product: PARIET, ENTERIC-COATED TABLET 10MG; DIN 02243796; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.